New treatment may help more patients survive cardiac arrest
The ARISE study will investigate a new experimental treatment for in-hospital cardiac arrest that may help more patients survive.
Cardiac arrest is a major health problem accounting for an estimated 15-20% of all deaths. Cardiac arrest is the sudden loss of heart function. The current standard treatment of cardiac arrest is chest compressions (also known as CPR), defibrillation and medicine. Even with these standard treatments, around 75% of patients do not survive due to their cardiac arrest inside the hospital.
If a cardiac arrest patient does not respond to standard treatment, the device used in this study, the Neurescue device, is placed. This device may help restart a patient’s heart and protect their brain during a cardiac arrest. The device is used while the patient will continue to receive standard treatment for the cardiac arrest and only once all other options have been attempted without success.
Most patients with cardiac arrest are not able to give consent, therefore this study has been FDA approved and approved by the Institutional Review Board (IRB) to enroll patients without their consent.
Ten (10) patients will be enrolled from April 2022 to September 2023. Significant risks to the study include kidney complications, paralysis, a blood clot or blockage in blood vessels, death, and neurological impairment.
Your opinion about this study is very important to us and therefore we kindly ask you to complete our survey at arisestudy.com. Your responses will remain anonymous. For more information about the ARISE study, please email [email protected].
To opt-out of this study, please email “opt-out” with your name and mailing address to [email protected]. You will receive an opt-out wrist bracelet to show that you do not wish to participate in this study.
Support our journalism.
Hyperlocal news is an essential force in our democracy, but it costs money to keep an organization like this one alive, and we can’t rely on advertiser support alone. That’s why we’re asking readers like you to support our independent, fact-based journalism. We know you like it—that’s why you’re here. Help us keep hyperlocal news alive in Long Beach.